Search global stocks & ETFs...Ctrl K
Learn Mode
REGN
Stock Profile
07-30
Recommended Metric
Score Card
Explore Scores Tab
3.80
Good
Valuation Score
Key Score
2.00
Bad
Management
4.00
Good
Growth
5.00
Very Good
Profitability
2.00
Bad
Fin. Health
4.00
Good
Dividends
4.00
Good
Analyst
3.00
Average
Insider Transactions
Explore Insider Tab ›Buy Transactions
Sell Transactions
Peers
Select stocks to compare
Price Targets & Ratings
View Analysis
1-year price targets, ending May 11, 2027
Current
$654
Baseline
High
$1,110
▲
69.63%
Avg
$882
▲
34.86%
Low
$667
▲
1.88%
Analyst Ratings based on 38 Analysts
Strong Buy
924%
Buy
1847%
Hold
1129%
Sell
000%
Strong Sell
000%
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. The company is headquartered in Tarrytown, New York and currently employs 15,410 full-time employees. The firm invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The firm is accelerating drug development using its proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and new classes of bispecific antibodies. VelociSuite consists of VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, VelociHum, and other related technologies. Its marketed products include EYLEA (aflibercept); Dupixent (dupilumab); Libtayo (cemiplimab); Ordspono (odronextamab); Kevzara (sarilumab); Itepekimab; Lynozyfic, and others.Read More